Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NKX019 in Systemic Lupus Erythematosus
NCT06518668Phase 1Enrolling by invitation
- Sponsor
- Hospital for Special Surgery
- Start
- Jul 2024
- Primary completion
- Dec 2026
- Modality
- CAR-T Cells, Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NKX019 in systemic lupus erythematosus (SLE), sponsored by Hospital for Special Surgery. Primary endpoint: Incidence of adverse events at 2 years. Started Jul 2024; status: enrolling by invitation.
02
Drugs
NKX019
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06518668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06518668.